Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis

Current Opinion in Neurology

Volumn 15, Issue 3, 2002, Pages 361-370

  Rieckmann, Peter ^a   Mäurer, Mathias ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; CALCIUM ANTAGONIST; CANNABINOID; CILIARY NEUROTROPHIC FACTOR; ESTROGEN; GLATIRAMER; GLUCOCORTICOID; INTERFERON BETA SERINE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; NATALIZUMAB; NEUROTROPHIC FACTOR; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROGESTERONE; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; AXONAL INJURY; DEMYELINATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MACROGLIA; MACROPHAGE; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; NEUROPROTECTION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AXONS; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; WALLERIAN DEGENERATION;

EID: 0036264075     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200206000-00022     Document Type: Review

References (107)

1. Immunological aspects of demyelinating diseases
2. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis
3. Axonal damage in multiple sclerosis lesions
4. Axonal transection in multiple sclerosis lesions
5. Axonal pathology in multiple sclerosis: A historical note
6. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences
7. Multiple sclerosis: More than inflammation and demyelination
8. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis
9. Future options for therapies to limit damage and enhance recovery
10. Mechanisms of tissue injury in multiple sclerosis: Opportunities for neuroprotective therapy
11. Regenerating myelin
12. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS
13. Randomized controlled trial of interferon-beta-1a in secondary progressive MS
14. Extended use of glatiramer acetate (Copaxon e) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
15. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
16. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
17. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
18. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis
19. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
20. Axonal loss in normal-appearing white matter in a patients with acute MS
21. On the molecular architecture of myelinated fibers
22. Axon-glia interaction and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin
23. Molecular biology of neurotrophic factors
24. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death
25. Disruption of the CNTF gene results in motor neuron degeneration
26. CNTF-deficiency deteriorates clinical course and histopathology in a murine model of experimental autoimmmune encephalomyelitis: A neurotrophic factor as outcome determinator of neuroinflammation
27. A null mutation in the CNTF gene is associated with early onset of multiple sclerosis
28. APOE genotype is a major predictor of long-term progression of disability in MS
29. Apolipoprotein Ee4 is associated with rapid progression of multiple sclerosis
30. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying the apolipoprotein epsilon 4 allele
31. Genetic models for CNS inflammation
32. Neurodegeneration: A failure of neuroregeneration?
33. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
34. Glutamate excitotoxicity in a model of multiple sclerosis
35. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage
36. Cytokine effects on glutamate uptake by human atrocytes
37. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains
38. Peroxynitrite formation within the central nervous system in active multiple sclerosis
39. Electrically active axons degenerate when exposed to nitric oxide
40. Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases
41. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis
42. Mechanism of myelin breakdown in experimental demyelination: A putative role for calpain
43. Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury
44. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: Involvement of metalloproteinases
45. A comparison of leucocyte responses to heat-killed bacillus Calmette-Guerin in different CNS compartments
46. Axonal damage induced by invading T cells in organotypic central nervous system tissue in vitro: Involvement of microglial cells
47. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage
48. Cytokin-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
49. Production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules
50. Induction of MHC class I genes in neurons
51. Transection of major histocompatibility complex I-induced neurites by cytotoxic T lymphocytes
52. + T lymphocytes is effected through the Fas/FasL, but not the perforin pathway
53. + T cells in a model for multiple sclerosis
54. Myelin antigen-specific CD8 T cells are encephalitogenic and produce severe disease in C57BL/6 mice
55. Clonal expansion of CD8 T cells dominate the cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction
56. Oligoclonal expansion of memory CD8+ T cells in the cerebrospinal fluid from multiple sclerosis patients
57. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis
58. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental autoimmune encephalomyelitis and humans with multiple sclerosis
59. Acquired channelopathies in nerve injury and MS
60. Transected neurites, apoptotic neurons, and reduced Inflammation in cortical multiple sclerosis lesions
61. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation?
62. Innate and adaptive immune responses can be beneficial for CNS repair
63. Concurrent validity of the MS functional composite using MRI as a biological disease marker
64. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis
65. T1 hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment
66. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS
67. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis
68. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vive using proton magnetic resonance spectroscopy
69. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'
70. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
71. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS
72. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1
73. Chemokine antagonist infusion promotes axonal sparing after spinal cord contusion injury in rat
74. Why treat early multiple sclerosis
75. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
76. Central nervous system inflammation: Can't live with it, can't live without it
77. Macrophage depletion impairs oligodendrocyte remyelination following lysotecithin-induced demyelination
78. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
79. Microglial phagocytosis of apoptotic inflammatory T cells leads to downregulation of microglial immune activation
80. Differential expression of BDNF in human cerebral and umbilical endothelial cells
81. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord
82. Mechanisms of calcium entry during axon injury and degeneration
83. Magnetic resonance imaging of multiple sclerosis: New insights linking pathology to clinical evolution
84. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy
85. Brain damage, sex hormones and recovery: A new role for progesterone and estrogen?
86. Estriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis
87. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a Th2 phenomenon?
88. Rate of pregnancy-related relapse in multiple sclerosis
89. Variations in cytokine mRNA expression during normal human pregnancy
90. Treatment of women with multiple sclerosis using the pregnancy hormone estriol: A pilot study
91. Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets
92. The side-effects of cyclosporine-A and tacrolimus
93. Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortatlized oligodendroglial cell line
94. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
95. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in lewis rats
96. A pilot study of pentoxifylline in multiple sclerosis
97. Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase
98. Phosphodiesterase type IV inhibitors: Potential in the treatment of multiple sclerosis?
99. Control of the survival/death decision by cannabinoids
100. Cannabinoids control spasticity and tremor in a multiple sclerosis model
101. Effect of CB1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity
102. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia and human monocytes
103. Is the therapeutic application of neurotrophic factors dead?
104. Gene delivery and gene therapy with herpes simplex virus-based vectors
105. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice
106. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis
107. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis